Dual MTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy

被引：0
|
作者：
Garcia-Garcia, C. [1 ]
Ibrahim, Y. H. [1 ]
Serra, V. [1 ]
Calvo, M. T. [1 ]
Aura, C. [1 ]
Perez, J. [1 ]
Rommel, C. [2 ]
Tabernero, J. [1 ]
Baselga, J. [3 ]
Scaltriti, M. [3 ]
机构：
[1] Vall dHebron Inst Oncol, Barcelona, Spain
[2] Intellikine Inc, La Jolla, CA USA
[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
10.1016/S0959-8049(12)71437-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
804
引用
收藏
页码：S192 / S192
页数：1
相关论文
共 50 条
  • [1] Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
    Garcia-Garcia, Celina
    Ibrahim, Yasir H.
    Serra, Violeta
    Teresa Calvo, Maria
    Guzman, Marta
    Grueso, Judit
    Aura, Claudia
    Perez, Jose
    Jessen, Katti
    Liu, Yi
    Rommel, Christian
    Tabernero, Josep
    Baselga, Jose
    Scaltriti, Maurizio
    CLINICAL CANCER RESEARCH, 2012, 18 (09) : 2603 - 2612
  • [2] Dual inhibition of mTORC1/C2 and HER2 results in maximal antitumor efficacy in preclinical model of HER2+breast cancer resistant to trastuzumab therapy
    De, Pradip Kr
    Sun, Yuliang
    Carlson, Jennifer H.
    Lin, Xiaoqian
    Dey, Nandini
    Leyland-Jones, Brian
    CANCER RESEARCH, 2015, 75
  • [3] Dual Fatty Acid Synthase and HER2 Signaling Blockade Shows Marked Antitumor Activity against Breast Cancer Models Resistant to Anti-HER2 Drugs
    Blancafort, Adriana
    Giro-Perafita, Ariadna
    Oliveras, Gloria
    Palomeras, Sonia
    Turrado, Carlos
    Campuzano, Oscar
    Carrion-Salip, Dolors
    Massaguer, Anna
    Brugada, Ramon
    Palafox, Marta
    Gomez-Miragaya, Jorge
    Gonzalez-Suarez, Eva
    Puig, Teresa
    PLOS ONE, 2015, 10 (06):
  • [4] Antitumor activity of lapatinib in combination with the dual mTORC1/2 inhibitor INK-128 in breast tumors resistant to anti-HER2 therapy
    Garcia-Garcia, Celina
    Ibrahim, Yasir H.
    Serra, Violeta
    Teresa Calvo, Maria
    Guzman, Marta
    Grueso, Judit
    Aura, Claudia
    Perez, Jose
    Jesen, Katti
    Liu, Yi
    Rommel, Christian
    Tabernero, Josep
    Baselga, Jose
    Scaltriti, Maurizio
    CANCER RESEARCH, 2012, 72
  • [5] Dual PI3K/mTOR and HER2 Blockade Results in Antitumor Efficacy in Preclinical Models of HER2+Breast Cancer Resistant to Trastuzumab Therapy
    De, P.
    Sun, Y.
    Dey, N.
    Leyland-Jones, B.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 114 - 115
  • [6] The perspective of anti-HER2 therapy for HER2 positive breast cancer
    Iwata, Hiroji
    ANNALS OF ONCOLOGY, 2015, 26 : 11 - 11
  • [7] Immune microenvironment dynamics of HER2 overexpressing breast cancer under dual anti-HER2 blockade
    Batalha, Sofia
    Gomes, Catarina Monteiro
    Brito, Catarina
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [8] HER2 testing and its predictive utility in anti-HER2 breast cancer therapy
    Advani, Pooja P.
    Crozier, Jennifer A.
    Perez, Edith A.
    BIOMARKERS IN MEDICINE, 2015, 9 (01) : 35 - 49
  • [9] TAS0728, a covalent binding, selective inhibitor of HER2, shows antitumor activity in HER2+tumor models resistant to established anti-HER2 therapy
    Irie, H.
    Fujioka, Y.
    Ito, K.
    Oguchi, K.
    Osawa, H.
    Funabashi, K.
    Shimamura, T.
    Nakagawa, F.
    Kawabata, R.
    Nagase, H.
    Uchida, J.
    Okubo, S.
    Matsuo, K.
    Utsugi, T.
    Iwasawa, Y.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E124 - E125
  • [10] BREAST CANCER BIOMARKERS AND HER2 TESTING AFTER 10 YEARS OF ANTI-HER2 THERAPY
    Ross, Jeffrey S.
    DRUG NEWS & PERSPECTIVES, 2009, 22 (02) : 93 - 106
12345